Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Report
  • Published:

Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study

International Journal of Impotence Research volume 19, pages 104–107 (2007)Cite this article

Abstract

The effectiveness of cabergoline in 50 men with psychogenic erectile dysfunction was investigated in a 4-month, randomized, placebo-controlled, double-blind study with validated psychological tests, and prolactin, follicle-stimulating hormone, luteinizing hormone and testosterone serum levels. Cabergoline treatment was well-tolerated and resulted in normalization of hormone levels in most cases. In the cabergoline-treated group, significant interactions between prolactin and testosterone serum concentrations were observed. Erectile function improved significantly. Sexual desire, orgasmic function, and the patient's and his partner's sexual satisfaction were also enhanced. Cabergoline may be an effective and safe alternative agent for men with psychogenic ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Cavallero R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E . Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65: 187–190.

    Article  Google Scholar 

  2. Krueger THC, Haake P, Haverkamp J, Kramer M, Exton MS, Saller B et al. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol 2003; 179: 357–365.

    Article  CAS  Google Scholar 

  3. Wittstock M, Benecke R, Dressler D . Cabergoline can increase penile erections and libido. Neurology 2002; 58: 831.

    Article  Google Scholar 

  4. De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova L et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89: 621–625.

    Article  CAS  Google Scholar 

  5. Wiltink J, Hauck EW, Phadayanon M, Weidner W, Beutel ME . Validation of the German version of the International Index of Erectile Function (IIEF) in patients with erectile dysfunction, Peyronie's disease and controls. Int J Impot Res 2003; 15: 192–197.

    Article  CAS  Google Scholar 

  6. Muellner M . Evidence based medicine. Springer: Wien, New York, 2002.

    Google Scholar 

  7. Hamilton M . Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1976; 6: 278–296.

    Article  Google Scholar 

  8. Hamilton M . The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55.

    Article  CAS  Google Scholar 

  9. Schulz P, Scholtz W, Becker P . Trier Inventory for the Assessment of Chronic Stress. Goettingen: Hogrefe, 2004.

    Google Scholar 

  10. Mac Donagh R, Ewings P, Porter T . The effect of erectile dysfunction on quality of life: psychometric testing of a new quality of life measure for patients with erectile dysfunction. J Urol 2002; 167: 212–217.

    Article  Google Scholar 

  11. Glick HA, McCarron TJ, Althof SE, Corty EW, Willke RJ . Construction of scales for the Center for Marital and Sexual Health (CMASH). Sexual Functionning Questionnaire. J Sex Marital Ther 1997; 23: 103–117.

    Article  CAS  Google Scholar 

  12. De Rosa M, Zarrilli S, Di Sarno A, Milano N, Gaccione M, Boggia B et al. Hyperprolactinemia in men. Endocrine 2003; 20: 75–82.

    Article  CAS  Google Scholar 

  13. Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK et al. Hormone-neurotrasmitter interactions in the control of sexual behavior. Behav Brain Res 1999; 105: 105–116.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Psychosomatic, Inntalklinik, Simbach/Inn, Germany

    M Nickel, D Moleda & W Rother

  2. University Clinic for Psychiatry 1, PMU, Salzburg, Austria

    M Nickel

  3. Department of Psychosomatic Medicine, Regensburg University Clinic, Regensburg, Germany

    T Loew

  4. Psychosomatic Outpatient Clinic, University Medicine Clinic, LMU, Munich, Germany

    F Pedrosa Gil

Authors
  1. M Nickel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Moleda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Loew
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Rother
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Pedrosa Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Nickel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nickel, M., Moleda, D., Loew, T. et al. Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. Int J Impot Res 19, 104–107 (2007). https://doi.org/10.1038/sj.ijir.3901483

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901483

Keywords

This article is cited by

Search

Advanced search

Quick links